Carregant...
Cost‐Effectiveness of Ivabradine for Heart Failure in the United States
BACKGROUND: Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure. This study assessed the cost‐effectiveness of adding ivabradine to background therapy in the United States from the perspective of a commercial or Medicare Advantage paye...
Guardat en:
| Publicat a: | J Am Heart Assoc |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4889192/ https://ncbi.nlm.nih.gov/pubmed/27153871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.116.003221 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|